IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
25.02
+0.52 (2.12%)
Jul 28, 2025, 4:00 PM - Market closed
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
The 13 analysts that cover IDEAYA Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $51.36, which forecasts a 105.28% increase in the stock price over the next year. The lowest target is $27 and the highest is $72.
Price Target: $51.36 (+105.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $66 → $72 | Buy | Maintains | $66 → $72 | +187.77% | Jul 28, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Jul 22, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $57 → $30 | Buy | Maintains | $57 → $30 | +19.90% | Jul 9, 2025 |
| Wells Fargo | Wells Fargo | Buy Initiates $44 | Buy | Initiates | $44 | +75.86% | Jun 26, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $63 → $66 | Buy | Maintains | $63 → $66 | +163.79% | May 22, 2025 |
Financial Forecast
Revenue This Year
15.11M
from 7.00M
Increased by 115.83%
Revenue Next Year
53.26M
from 15.11M
Increased by 252.50%
EPS This Year
-3.28
from -3.36
EPS Next Year
-3.09
from -3.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 35.9M | 183.2M | 225.2M | ||
| Avg | 15.1M | 53.3M | 147.4M | ||
| Low | n/a | 6.0M | 99.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 413.0% | 1,112.5% | 322.9% | ||
| Avg | 115.8% | 252.5% | 176.8% | ||
| Low | - | -60.4% | 85.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.75 | -2.22 | -1.67 | ||
| Avg | -3.28 | -3.09 | -2.56 | ||
| Low | -3.62 | -4.00 | -3.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.